HealthQuill Orphan Drug Designation
Switzerland’s Basilea Pharmaceutica Ltd. has received an additional $39 million from the US-based Biomedical Advanced Research and Development Authority to continue to advance the end-stage trials of antifungals.
Drugs Medical Pharma

Basilea gets $39 million additional funds from US’s BARDA

HQ Team July 8, 2025: Switzerland’s Basilea Pharmaceutica Ltd. has received an additional $39 million from the US-based Biomedical Advanced Research and Development Authority to.

Read More
The US Food and Drug Administration has approved Nuvation Bio Inc.’s medicine for adults who have a rare type of lung cancer caused by a specific genetic change.
Drugs Health Pharma

US drug regulator greenlights Nuvation’s rare lung cancer medicine

HQ Team June 11, 2025: The US Food and Drug Administration has approved Nuvation Bio Inc.’s medicine for adults who have a rare.

Read More